文献速递细菌感染、耐药与抗菌药物

Tedizolid与其他口服抗菌药对葡萄球菌的药效学相互作用

Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究通过肉汤微量稀释法和时间杀菌曲线,评估tedizolid与利福平、复方磺胺甲噁唑、多西环素和莫西沙星对45株葡萄球菌的体外药效学相互作用。结果显示相互作用多为无关(80%),tedizolid与利福平或多西环素偶见协同,与莫西沙星对3/10株出现拮抗,提示应避免tedizolid联合莫西沙星。

要点

  • Tedizolid与其他口服抗葡萄球菌药联合多表现为无关作用。
  • Tedizolid联合利福平最可能提高活性,但协同不普遍。
  • 应避免Tedizolid联合莫西沙星,因存在拮抗风险。

核心结论

  • Tedizolid与利福平联合最可能改善活性,但协同并非普遍存在。
  • Tedizolid与莫西沙星联合应避免,因存在拮抗风险。
  • 添加其他口服抗葡萄球菌药至tedizolid可能不太可能改善杀菌,但需进一步研究。

研究设计与样本

  • 对45株葡萄球菌便利样本用肉汤微量稀释法测定tedizolid、利福平、复方磺胺甲噁唑、多西环素和莫西沙星的MIC。
  • 选取7株MRSA和3株表皮葡萄球菌,以0.5×MIC浓度进行时间杀菌曲线评估。

主要发现

  • 45株中3株对tedizolid非敏感(MIC=1 mg/L),MIC90为0.5 mg/L。
  • Tedizolid与其他药物相互作用大部分为无关(80%)。
  • Tedizolid与多西环素对2/10株、与利福平对3/10株显示协同。
  • Tedizolid与莫西沙星对3/10株显示拮抗。

关键数值与推荐

  • 协同定义为联合较最活跃单药降低≥2 log10 cfu/mL。
  • 拮抗定义为联合较最活跃单药增长≥1 log10 cfu/mL。

临床怎么用

  • 临床联合用药时可优先考虑tedizolid联合利福平,但需注意协同不普遍。
  • 避免tedizolid与莫西沙星联合使用。

局限性

  • 样本为便利样本,菌株数量有限且部分药物敏感性可变。
  • 时间杀菌曲线仅评估10株菌,结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tedizolid is an orally bioavailable oxazolidinone with once-daily dosing and broad-spectrum Gram-positive activity. Combination therapy is commonly indicated to improve efficacy against difficult-to-treat pathogens and biofilms. There are no studies describing the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials. METHODS: MICs of tedizolid, rifampicin, trimethoprim/sulfamethoxazole, doxycycline and moxifloxacin were determined by broth microdilution against a convenience sample of 45 staphylococcal isolates. Seven MRSA isolates and three Staphylococcus epidermidis were evaluated by time-kill using concentrations equal to 0.5× the MIC. These strains had variable susceptibility to the investigated antimicrobials. Synergy was defined as a ≥2 log 10 cfu/mL reduction of the combination over the most active single agent, antagonism was defined as ≥1 log 10 cfu/mL growth compared with the most active single agent, and other interactions were indifferent. RESULTS: Three of 45 strains tested were non-susceptible to tedizolid (MIC = 1 mg/L), but the MIC 90 was 0.5 mg/L. Interactions between tedizolid and other agents were largely indifferent (80%). Tedizolid was synergistic with doxycycline and rifampicin against 2/10 and 3/10 strains, respectively. Tedizolid was antagonistic with moxifloxacin against 3/10 strains. Other interactions were indifferent. CONCLUSIONS: The addition of rifampicin to tedizolid appears to be the most likely to improve activity but synergy was not universal. The combination of tedizolid plus moxifloxacin should be avoided due to the risk of antagonism. The addition of other orally bioavailable anti-staphylococcal agents to tedizolid may be unlikely to improve killing but further research is warranted to assess the impact of these combinations on resistance prevention, or against biofilm-embedded organisms.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Werth BJ. Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother. 2017. PMID: 28158617. doi:10.1093/jac/dkw588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。